The following table summarizes the components of stock-based compensation expense recognized in the Company’s condensed statements of operations and comprehensive loss during the three months ended March 31, 2026 and 2025 (in thousands):


	Three Months Ended March 31,
	2026		2025
Research and development	$	154	$	126
General and administrative		535		418
Total stock-based compensation expense	$	689	$	544

During the three months ended March 31, 2026, the Company granted 62,350 RSUs with a weighted-average grant date fair value of $79.37 per unit, of which 36,900 RSUs are subject to performance-based vesting conditions related to the satisfaction of a regulatory milestone. As of March 31, 2026, the Company had 38,920 RSUs outstanding subject to performance-based vesting conditions, of which none are considered probable of achievement.